FDA
-
-
-
-
-
-
-
JPMorgan Starts Larimar Therapeutics (LRMR) at Overweight
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush
-
-
-
-
-
-
-
Larimar reports positive data from Friedreich's ataxia drug study
-
-
-
-
-
-
-
Larimar Therapeutics publishes nonclinical data on nomlabofusp
-
-
-
-
-
-
-
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
-
-
-
-
-
-
-
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Reports Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
-
328,515 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

